Sign in / Join
Sign in
Recover your password.
A password will be e-mailed to you.
Author
DengYue Medicine 9 posts 0 comments
DengYue Medicine is a Hong Kong-based pharmaceutical wholesaler specializing in the export of Chinese medicines. With a product portfolio of over 30,000 types, our offerings include Chinese innovative drugs, oncology and hematology treatments, orphan medicines, and a wide range of hospital-use pharmaceuticals. Through an extensive global trade network, we are committed to ensuring the worldwide supply of high-quality medicines to meet diverse healthcare needs. We consistently prioritize the safety, efficacy, and stable quality of our products, ensuring that all medicines comply with international certification standards.
In the past few years, China’s pharmaceutical industry has begun to attract worldwide attention. Headlines now speak of “China’s biotech boom” and “global firms licensing Chinese drugs.” While some reports may be overly!-->!-->!-->…
Caught Between Giants: How Can Keymed Biosciences’ Stapokibart Injection Break Through the…
On September 12, 2024, Keymed Biosciences announced that its independently developed Category 1 innovative drug, Stapokibart Injection, had been officially approved for marketing by China’s National Medical!-->!-->!-->…
A Traveler’s Guide to Purchasing Innovative Chinese Medicines in China
Traveling to China offers more than just iconic landmarks like the Great Wall or bustling cities like Shanghai—it's also a gateway to exploring the country's cutting-edge pharmaceutical innovations. China has emerged as a global leader in!-->…
China NMPA Approves Xeligekimab Injection (Jinlixi) for Moderate-to-Severe Plaque Psoriasis
On September 12, 2024, China’s NMPA officially approved Xeligekimab Injection (Jinlixi), developed by Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd., for the treatment of adult patients with moderate-to-severe plaque psoriasis!-->!-->!-->…
China’s Oncology Innovation Gains Momentum: Golixitinib Approved for r/r PTCL
Exciting news from China’s biopharma sector — the NMPA has conditionally approved Golixitinib Capsules (Gaoruizhe), developed by Dizal (Jiangsu) Pharmaceutical, for the treatment of relapsed or refractory peripheral T-cell lymphoma!-->!-->!-->…
China’s Pharmaceutical Exports Show New Momentum Amid Global Trade Shifts
The landscape of China’s pharmaceutical exports is entering a period of accelerated transformation, driven by changing global trade patterns, the rise of innovative drug development, and the diversification of global healthcare demand.
!-->!-->!-->…